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Abstract: Eslicarbazepine is a new dibenzazepine antiepileptic agent. It is a high affinity 
antagonist of the voltage-gated sodium channel. It is closely related to both carbamazepine and 
oxcarbazepine. Eslicarbazepine has similar affinity to inactivated sodium channels (channels in 
just activated neurons) as carbamazepine, and greater efficacy in animal models of seizure than 
oxcarbazepine. In human placebo-controlled trials of a single daily dose of eslicarbazepine added 
to other anti-epileptic agents, significant seizure reductions occurred with 800 and 1200 mg 
daily, with nearly half of the patients experiencing a greater than 50% reduction in seizure 
frequency. Adverse events (AEs) occurred in over 50% of patients receiving therapeutic doses 
of eslicarbazepine (compared to 31.4%–44.7% of placebo-treated subjects), but were generally 
mild or moderate. Eight to 19.6% of eslicarbazepine treated patients discontinued due to AEs 
(compared to 3.9%–8.5% of placebo-treated subjects). In these patients receiving combination 
anticonvulsant therapy, the most common AEs were dizziness, nausea and vomiting, somnolence, 
and diplopia. Eslicarbazepine is an effective and reasonably well-tolerated adjunct in patients 
with suboptimal control of their partial seizures.
Keywords: eslicarbazepine, licarbazepine, voltage-gated sodium channel, partial-onset seizures, 
epilepsy
Seizures are among the most common chronic neurologic problems encountered in 
medical practice. Focal- or partial-onset epilepsy, defined as recurrent, unprovoked 
episodes of abnormal electrical activity that begin in one part of the brain, is the 
most common form of epilepsy diagnosed in adults with an annual incidence of 10 to 
15 per 100,000 in young- to middle-aged adults and an annual incidence as high as 
70 per 100,000 in adults over age 60.1 The prevalence of partial onset epilepsy in 
the United States and Europe has been estimated between 3 and 10 per 1000.2,3 The 
goal of seizure management is complete seizure control with minimal side effects. 
Quality of life (QoL) studies have suggested that patients who suffer even a single 
seizure per year have a reduced QoL.4 Seizures, especially convulsive seizures, are 
associated with significant morbidity and mortality, including a higher incidence 
of accidental drowning, fractures, head and soft-tissue injuries, and serious motor 
vehicle accidents.5 Severe burn injuries are also more likely as patients with epilepsy 
are overrepresented in burn units.6 The economic and social impact of uncontrolled 
seizures is also significant. Lost productivity due to seizures is a major ‘indirect cost’ 
of epilepsy.7 Driving restrictions in the United States vary by state with some states 
prohibiting driving for as long as 12 months after a single seizure.8Therapeutics and Clinical Risk Management 2010:6 104
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Complete seizure control is not easily achieved. In one 
large observational study, only 47% of patients became sei-
zure free following initial monotherapy with an appropriately 
chosen anti-epileptic drug (AED), and only 63% of patients 
ultimately became seizure-free with medical management.9 
Side-effects of AEDs are common, and frequently contribute 
to non-compliance. Newer AEDs, while not necessarily more 
effective at controlling seizures, clearly have fewer drug-
drug interactions and may be better tolerated.10 Laboratory 
monitoring for hematologic and metabolic effects is often 
unnecessary with newer AEDs, although idiosyncratic reac-
tions still occur. On the other hand, potential teratogenicity 
and effects of long-term therapy are better understood in older 
AEDs. Given the prevalence of epilepsy which is refractory 
to currently available medications, new agents with favorable 
efficacy and tolerability are desirable.
Eslicarbazepine acetate (Stedesa™ in the United 
States; Zebinix®, Exalief® in Europe; chemical name 
(S)-(–)-10-acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-
5-carboxamide; development name BIA 2-093), is a new 
dibenzazepine that has documented efficacy as an adjunct 
agent in patients with inadequately controlled partial-onset 
seizures. It is currently being reviewed by the United States 
Food and Drug Administration and has been approved by 
the European Medicines Agency (EMEA) in the European 
Union. Additionally, it is undergoing investigation for mono-
therapy treatment of partial epilepsy and bipolar illness.
Pharmacology
Eslicarbazepine is administered as the acetate salt which is 
rapidly and nearly completely reduced by esterases in the liver to 
the S enantiomer, S-licarbazepine or eslicarbazepine (BIA 2-005) 
(Figure 1). This is the active form in the brain and accounts for 
approximately 95% of the metabolic product of the parent pro-
drug.11 The inactive R enantiomer and oxcarbazepine account for 
less than 5% of the metabolic product.11,12 It is important to note 
that eslicarbazepine is the active metabolite of oxcarbazepine. 
Oxcarbazepine is actually a pro-drug that is metabolized into 
both the S and R enantiomers of licarbazepine at a ratio of 4 or 
5 to 1.12,13 The nearly complete conversion of eslicarbazepine 
acetate to the active eslicarbazepine is believed to be the mecha-
nism leading to fewer adverse neurological consequences in rats 
than oxcarbazepine,14 and more consistent anti-seizure effect than 
oxcarbazepine in a rat electroshock seizure model.12
Mechanism of action
Eslicarbazepine binds avidly and blocks the inactivated 
voltage-gated sodium channel (VGSC). The VGSC is the 
major source of sodium entry when a neuron depolarizes, 
and consequently allows for the action potential to propagate. 
VGSCs have 3 states. In the deactivated or resting state, the 
VGSC is closed, but the channel is responsive to a depolar-
ization signal. When the cell depolarizes, the VGSC opens 
to allow sodium ion entry. After the action potential, the 
VGSC enters an inactivated state, in which it is closed and 
not responsive to voltage changes.15 Eslicarbazepine binds to 
the inactivated form of the VGSC and prevents its reversion to 
the receptive resting or deactivated form.16,17 This means that 
eslicarbazepine binds to more active neurons preferentially. 
This mechanism is shared by carbamazepine, oxcarbazepine, 
and other anticonvulsants.17,18 The affinity of eslicarbazepine 
to the inactivated form of the VGSC is similar to that of carba-
mazepine, but its affinity to the resting form of VGSC is some 
3 times less.12,17 This suggests that eslicarbazepine is less 
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Figure 1 Eslicarbazepine is formed by reduction of the acetate salt (shown on the right) or may be found as the predominant (4:1) active metabolite of oxcarbazepine (middle). 
Carbamazepine and its active epoxide metabolite are shown on the left. Reprinted with permission from Almeida L, Soares-da-Silva P. Eslicarbazepine acetate (BiA 2-093). 
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likely to bind to normally active neurons, and therefore, less 
likely to cause adverse neurological consequences. Indeed 
when compared with either carbamazepine or oxcarbazepine, 
eslicarbazepine had less neurologic impairment in rats,14 and 
was less toxic to cultured hippocampal neurons.19
Pharmacokinetics
Bioavailability of eslicarbazepine in a liquid suspension or 
tablet formulations is equivalent.20 Food does not affect the 
absorption or subsequent drug levels.21,22 The possible effect 
of gender on pharmacokinetics was studied in 24 healthy 
subjects (12 male) who received eslicarbazepine for 8 days. 
There were no significant differences in the bioavailability 
of the drugs, although women absorbed more drug than 
men.23 Finally, age did not affect absorption when young 
(age 18–40 years, n = 12) and older (age  65 years, n = 12) 
subjects received 600 mg in a single dose.11
The time to maximal serum concentration for the thera-
peutic doses of 900 or 1200 mg/day, or up to 2400 mg/day, 
ranges from 2.3 to 4 hours.12 Both the rate and the area under 
the curve (AUC) increased in a linear fashion with increasing 
dose (400–2400 mg/day). The effective half-life of eslicar-
bazepine is approximately 20 to 24 hours, with steady state 
being reached in 4 to 5 days.12
Eslicarbazepine acetate is metabolized to eslicarbazepine 
very rapidly in the liver. Levels of the parent drug, eslicar-
bazepine acetate, are too low to be measureable after single 
or multiple doses.12 Eslicarbazepine is eliminated exclusively 
by the kidney and 91% of the drug is recovered in the urine.24 
Clearance from the plasma occurs at a consistent rate of 20 to 
30 mL/min.12 Approximately 20% of the dose is recovered in 
the urine after 12 hours, and 40% within 24 hours.12,25 Subjects 
with moderate hepatic impairment (n = 8) break down eslicar-
bazepine acetate more slowly, so that its levels can actually 
be detected, but this difference does not significantly alter 
the pharmacokinetics.24 Subjects with mild renal impairment 
(n = 8) eliminate eslicarbazepine more slowly than healthy 
controls (10.2 mL/min vs 17.3 mL/min in controls), but this 
not clinically significant.26 However, subjects with moderate 
(n = 8) or severe renal impairment (n = 8) clear eslicarbazepine 
much more slowly (3.7 mL/min and 1.5 mL/min, respec-
tively).26 Eslicarbazepine is cleared with dialysis in subjects 
with end-stage kidney disease requiring dialysis.26
Enantiomer-specific levels can be measured with high 
performance liquid chromatography separation and ultra-
violet light detection method.27 Levels at therapeutic doses 
ranged from 4.7 ± 4.0 µg/mL for 800 mg/day to 8.9 ± 
6.6 µg/mL for 1200 mg/day.28
Pharmacokinetic interactions have been observed 
between eslicarbazepine and other commonly used antiepi-
leptic drugs, similar to interactions seen with oxcarbazepine 
(Table 1).29 Steady state levels of eslicarbazepine were asso-
ciated with a significant increase in both phenytoin and phe-
nobarbital, possibly due to inhibition of the hepatic enzyme 
CYP2C19.29 Conversely, phenytoin and phenobarbital 
increased clearance of eslicarbazepine, and a 33% decrease 
in eslicarbazepine exposure was noted with concomitant 
phenytoin therapy.29 Small, possibly insignificant increases 
in clearance of topiramate, lamotrigine and carbamazepine 
were seen with concomitant use of eslicarbazepine, while a 
significant increase in eslicarbazepine clearance was noted 
with concomitant carbamazepine therapy.29 Other commonly 
used medications which may be affected by eslicarbazepine 
include warfarin and hormonal contraceptives.12 Eslicarbaze-
pine may lower levels of ethinylestradiol, possibly interfer-
ing with the efficacy of certain hormonal contraceptives, 
and may increase levels of tolbutamide, a first generation 
sulfonylurea.12 There are no kinetic interactions between 
eslicarbazepine and digoxin,30 or metformin31 when studied 
in healthy subjects taking both medications.
Efficacy studies
Eslicarbazepine has been shown to be effective in several 
animal models of epilepsy. In maximal electroshock seizures, 
eslicarbazepine was equal to carbamazepine, and superior to 
oxcarbazepine at 2 and 4 hours after the dose. At 8 hours after 
dose, all three drugs were equivalent.12 Eslicarbazepine was 
equivalent to carbamazepine in prevention of seizures in the 
amygdala kindling model.12 Furthermore, eslicarbazepine has 
been shown to be effective in the control of seizures induced 
Table 1 Summary of potential pharmacokinetic interactions 
between eslicarbazepine and other medications29
  Effect of eslicarbazepine  
on other drugs
Effect of other drugs 
on eslicarbazepine
Phenytoin ↑↑ ↓
Phenobarbital ↑↑ ↓?
Topiramate ↓? ↔
Lamotrigine ↓? ↔
Carbamazepine ↓? ↓
valproate ↔ ↔
Levetiracetam ↔ ↔
warfarin ↓? ↔
Ethinylestradiol ↓ ?
Tolbutamide ↑ ?Therapeutics and Clinical Risk Management 2010:6 106
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by proconvulsant agents such as metrazole, bicuculline, 
4-amino-pyridine,12 latruncullin A,32 and picrotoxin.33
In humans, the clinical trials have focused on partial-onset 
seizures. In the first published study, 143 patients with 4 
partial onset seizures/month, were recruited in a 12-week, multi-
center, randomized, double-blind, placebo-controlled compari-
son of eslicarbazepine once daily (n = 50), twice daily (n = 46), 
or placebo (n = 47) added to their existing anticonvulsant 
regimen.34 The dosage of eslicarbazepine was increased every 
4 weeks from 400 mg/day to 800 mg/day, to 1200 mg/day. One 
hundred thirteen (78.5%) patients completed the study. Mean 
age was approximately 39, and mean body mass index (BMI) 
was approximately 25. Nearly half (40.6%) were male.34
Partial seizures with secondary generalization were the most 
common (77.6%), followed by complex partial seizures (74.8%), 
and simple partial seizures (32.9%). Concomitant anticonvul-
sants consisted of: valproic acid (65.0%), topiramate (30.8%), 
lamotrigine (30.1%), clonazepam (15.4%), and phenytoin 
(7.7%). Patients receiving oxcarbazepine were excluded from 
the study. Phenytoin was over represented in the placebo group 
(17% of placebo treated patients) compared to single daily dose 
group (2%) or twice daily dose group (4%).34
Response was defined as a minimum of 50% reduction 
in seizure frequency versus baseline. Single daily dosed esli-
carbazepine was more effective than placebo (54% vs 28%, 
respectively; 90% CI =  −∞, −14, P = 0.008). Twice daily 
dosing was not significantly better than placebo (41% vs 28%, 
respectively; 90% CI = −∞, −1, P = 0.12). The greatest reduction 
in seizure number occurred in subjects receiving a single dose of 
1200 mg/day with a 60% reduction compared to a 30% reduction 
in those receiving placebo (P = 0.002).34 Elimination of seizures 
occurred in 24% of those receiving eslicarbazepine compared 
to only 9% of those receiving placebo (P  0.05).34
In a similar, larger study, 402 patients were recruited in 
a 12-week, randomized, double-blind, placebo-controlled 
study of single daily dose of 400 mg (n = 100), 800 mg (n = 
98), 1200 mg (n = 102), or placebo (n = 102).28 Of the 402 
patients, 330 (82%) completed the study. The mean age was 
39 years (range 18–76 years). Half (51%) were women, and 
all were Caucasian. The mean BMI was 24.5. Most patients 
were receiving 2 concomitant anticonvulsants (n = 257, 
63.9%), only 2 were receiving 3 anticonvulsants, and the 
remainder (n = 143, 35.6%) were taking only one concomi-
tant anticonvulsant. The most common concomitant anticon-
vulsant was carbamazepine (58.5%), followed by lamotrigine 
(26.1%), valproic acid (25.6%), topiramate (13.7%), leveti-
racetam (8.5%), phenobarbital (8.2%), clonazepam (7.5%), 
and gabapentin (5.5%) (oxcarbazepine excluded).28
The most common seizure type was complex partial 
seizures (69.7%). Nearly half of the patients had secondarily 
generalized seizures (46.3%) and simple partial seizures 
(44.0%). A small fraction had unclassified seizures (4.5%).28 
Duration of epilepsy was approximately 21 years, and the 
mean baseline seizure frequency was 2.9 seizures/week.
There was a dose related increase in the fraction of patients 
who responded (50% reduction in seizure frequency). 
Twenty percent of placebo-treated patients responded, com-
pared to 23% of those receiving eslicarbazepine 400 mg/day 
(ns), 34% of 800 mg/day (P  0.05), and 43% of 1200 mg/day 
(P  0.001).28 The likelihood of being free of seizures was 
only slightly higher with eslicarbazepine compared to placebo 
(8% of those receiving 1200 mg/day, P  0.05, 4% of those 
receiving 800 mg/day, ns, 2% of those receiving 400 mg/day, 
ns, and 2 % of those receiving placebo).28 The statistical 
methodology used in this study of the last observation carried 
forward generally underestimates the utility of the drug.
There is only one published study in a paediatric 
population.35 Eleven young children (ages 2–7 years, mean age 
4.1 ± SD 1.4 years), 8 older children (7–11 years, mean age 
9.1 ± 1.6 years), and 10 adolescents (12–17 years, mean 
age 14.5 ± 1.6 years) were given single daily doses of esli-
carbazepine in an open fashion. Forty-one percent were male. 
The majority were on 3 concomitant anticonvulsants (55.2%), 
nearly one-third were on 2 anticonvulsants (27.6%), and the 
rest were on 1 anticonvulsant (17.2%). The most common 
concomitant agents were lamotrigine (65.5%) and valproic 
acid (65.5%), followed by topiramate (48.3%), clonazepam 
(27.6%), phenobarbital (13.8%), and gabapentin (10.3%).35
Eslicarbazepine doses were initiated at 5 mg/kg/day 
for 4 weeks, and increased to 15 mg/kg/day for an additional 
4 weeks, and then to 30 mg/kg/day (or 1800 mg/day, which-
ever was less) for the last 4 weeks.35 Young children and 
adolescents experienced a dose related reduction in seizure 
frequency. In young children there was a 28.2%, 24.8%, 
and 40.6% reduction with doses of 5, 15, and 30 mg/kg/day, 
respectively. In adolescents there was a 17.1%, 31.7%, and 
43.1% reduction in seizure frequency with ascending doses. 
This pattern was not observed in older children (11.7%, 5.0%, 
and 12.2% reduction in seizure frequency at doses of 5, 15, 
and 30 mg/kg/day).35
Safety and tolerability
Eslicarbazepine  does  not  form  the  10–11  epoxy-
carbamazepine metabolite that is formed when carbamaze-
pine is prescribed. Consequently, it does not carry the same 
adverse consequences of that drug. However, when given Therapeutics and Clinical Risk Management 2010:6 107
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as an add-on drug to other anticonvulsants in a placebo-
controlled fashion, eslicarbazepine is associated with 
adverse events (AEs) in 41% to 61% of subjects (Table 2). 
In one study of 143 patients, the overall rate of AEs was not 
significantly different than placebo (ie, concomitant anti-
convulsant) (Table 2).34 In a study of 402 patients, AEs for 
the highest dose were twice as common as seen in placebo 
(ie, concomitant anticonvulsant) (Table 2).28 The likeli-
hood of adverse consequence is dose related with a higher 
rate of discontinuation for AE at higher doses (Table 2). 
The adverse effect profile is similar to that seen with both 
carbamazepine and oxcarbazepine and likely reflects a 
common mechanism of action. In all of the studies, there 
was only one death, a placebo-treated patient (ie, receiving 
concomitant anticonvulsants) who died from hypothermia. 
Electrocardiogram changes, specifically a mild prolonga-
tion of the PR interval, have been observed in patients 
taking eslicarbazepine.29 In recommending approval of 
eslicarbazepine in Europe, the European Medicines Agency 
advised a contraindication to the administration of eslicar-
bazepine to patients with 2nd or 3rd degree heart block 
and caution with co-administration of any drugs known to 
increase the PR interval.29
There were no significant changes in blood cell parameters 
or serum sodium levels. Among the two placebo-controlled 
studies, there were 4 cases of abnormal laboratory find-
ings. One case of hyponatremia (123 mmol/L) occurred 
in a patient receiving eslicarbazepine 800 mg once daily 
with concomitant carbamazepine and a baseline sodium of 
133 mmol/L.28 Additionally there was one case each of mild 
electrolyte imbalance, mild anemia, and a moderate elevation 
of creatine kinase.34
The overall plasma levels of eslicarbazepine varied in 
a linear fashion with dose over the therapeutic dose range 
(Table 3).28 None of the studies reported side effects as a 
function of concomitant anticonvulsant medication. This is 
an important point since AEDs with a similar mechanism 
(sodium channel blockade) might have an additive effect 
on observed AEs.
Among 29 children receiving eslicarbazepine in addi-
tion to other anticonvulsants, 21 subjects reported 54 AEs.35 
The frequency of reported AEs varied with dose so that 
11 occurred with low dose of 5 mg/kg/day, 15 occurred with 
the moderate dose of 15 mg/kg/day, and 28 were reported 
with the high dose of 30 mg/kg/day.35 All AEs at lower doses 
were mild. At 30 mg/kg/day there were 9 moderate AEs and 
2 severe AEs. Moderate AEs included somnolence (n = 3), 
vomiting (n = 2), diplopia (n = 2), dizziness (n = 1), and 
disequilibrium (n = 1). The severe cases were both related 
to worsening seizure disorder.35
Conclusions
Eslicarbazepine acetate is a prodrug which is rapidly and 
almost completely metabolized to the active metabolite (S) 
licarbazepine. It is a member of the dibenzazepine family, 
which includes carbamazepine and oxcarbazepine. In animal 
studies, it has similar potency to the active metabolite of carba-
mazepine with fewer adverse effects and interactions, includ-
ing cytochrome oxidases. Its preferential binding to VGSC 
in the inactivated state should result in selective inhibition of 
the most rapidly firing sodium channels, thereby limiting the 
excessive neuronal activity of seizures. It does not form the 
epoxide intermediate which is thought to be responsible for 
many of the adverse effects of carbamazepine. Its estimated 
half-life of 20–24 hours makes once-daily dosing a possibility. 
Table 2 Summary of percentage of adverse events across two placebo-controlled trials27,33
Adverse  
event (AE)
Placebo Eslicarbazepine  
400 mg/day
Eslicarbazepine   
800 mg/day
Eslicarbazepine   
1200 mg/day
Eslicarbazepine  
variable dose
Any AE 31.4 44.0 50.0 60.8 39.6
Dizziness 2.0 4.0 14.3 13.7 4.1
Headache 5.9 5.0 9.2 10.8 5.2
Diplopia 0 2.0 7.1 10.8 0
Somnolence 2.0 6.0 9.2 9.8 4.1
vertigo 1.0 2.0 2.0 5.9 0
AE leading to  
discontinuation
3.9  4.0  8.2  19.6  7.3 
Table 3 Eslicarbazepine levels as a function of dose27
  400 mg/day 800 mg/day 1200 mg/day
Eslicarbazepine 
level (µg/mL)
2.4 ± 2.2 4.7 ± 4.0 8.9 ± 6.6Therapeutics and Clinical Risk Management 2010:6 108
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Dosage adjustments will be necessary in patients with 
moderate to severe renal impairment. Eslicarbazepine may 
affect levels of other medications including phenytoin, war-
farin and estrogen-containing oral contraceptives, and certain 
enzyme-inducing AEDs may lower levels of eslicarbazepine. 
A contraindication to eslicarbazepine has been recommended 
in patients with 2nd or 3rd degree heart block, otherwise 
eslicarbazepine appears to be very safe. Efficacy has been 
demonstrated in at least three clinical trials of eslicarbazepine 
as adjunctive therapy for seizures, with a significant reduction 
in seizures as compared to placebo. Eslicarbazepine was well-
tolerated in these trials, with the most common side effects 
being dizziness, nausea, vomiting, somnolence and diplopia. 
Hyponatremia, an idiosyncratic reaction occasionally seen 
with oxcarbazepine, was only reported in one study patient 
who was on both eslicarbazepine and carbamazepine.
The published studies investigated a relatively small 
number of patients with few comorbid medical problems. 
The effectiveness of eslicarbazepine in a typical clinical 
population still needs to be investigated. Initial use of esli-
carbazepine will likely be as adjunctive therapy in adults 
with complex partial seizures who may be on a variety of 
other medications, including those affected by the CYP3A4 
(including certain calcium channel blockers and zonisamide) 
and the CYP2C19 enzyme systems. Additionally, an exami-
nation of the side effect profile may be warranted on patients 
on other psychotropics (eg, antidepressants or antipsychotic 
medications) or cardiovascular agents that may accentuate the 
AE profile of eslicarbazepine. Finally, a study of endocrino-
logic effects of ESL may be warranted as changes in thyroid 
function36,37 and vitamin D levels38,39 have been observed in 
adults and children on oxcarbazepine and decreased bone 
mineral density has been observed in pediatric patients 
receiving oxcarbazepine.39
In the past few years, as AEDs with less toxicity and 
fewer interactions have become available, emphasis on 
monotherapy in treatment resistant epilepsy has begun to give 
way to a sort of ‘rational polytherapy’ as means of control-
ling seizures,40,41 by using smaller doses of a combination 
of AEDs with different mechanisms of action to attain the 
goal of complete seizure control with fewer side-effects. As 
a group, the sodium channel blockers are among the most 
frequently prescribed medications in the management of epi-
lepsy. Although a direct comparison has not been performed, 
eslicarbazepine may be better tolerated and more effective 
in controlling partial onset seizures than oxcarbazepine. 
The added benefit of once-daily dosing, which is not possible 
with carbamazepine or oxcarbazepine, may improve patient 
compliance with therapy and thereby further improve seizure 
control. Eslicarbazepine appears to be a safe and effective 
addition to the armamentarium of physicians managing 
patients with epilepsy.
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